Beleodaq (belinostat) / Spectrum Pharma, Assertio, Valerio Therap, Aurobindo 
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beleodaq (belinostat) / Aurobindo, Assertio
2017-002561-21: Study of addition of belinostat to chemotherapy before surgery in patients with Thymic Epithelial Tumors (TET)

Ongoing
3
100
Europe
Belinostat, Powder for solution for infusion, Beleodaq (in the USA)
IFCT, Onxeo
Locally advanced potentially resectable Thymic Epithelial Tumors, Locally advanced Thymus Tumors, Diseases [C] - Cancer [C04]
 
 
NCT06561048: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Not yet recruiting
3
150
NA
Soquelitinib, CPI-818, Belinostat, Beleodaq®, Pralatrexate, Folotyn®
Corvus Pharmaceuticals, Inc.
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
02/26
09/27
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT02137759: MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Active, not recruiting
2
29
US
Standard Radiation Therapy, Standard Temozolomide, Temodar, Belinostat, Beleodaq, PXD101
Emory University, Johns Hopkins University, Spectrum Pharmaceuticals, Inc, National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Glioblastoma Multiforme of Brain
08/23
08/24
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
2
50
US
Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar
University of Virginia, Celgene
PTCL
06/26
06/28
NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
Binimetinib, Mektovi, ARRY-162, Belinostat, Beleodaq
H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Acrotech Biopharma Inc.
Metastatic Uveal Melanoma
12/24
12/24
NCT04184869: Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Completed
1
8
US
Belinostat, beleodaq, Atazanavir, Reyataz
Acrotech Biopharma Inc., Axis Clinicals Limited
Solid Tumor, Hematological Malignancies
12/22
03/23
NCT04703920: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Recruiting
1
25
US
Talazoparib, Belinostat
University of Michigan Rogel Cancer Center, Pfizer, Acrotech Biopharma Inc.
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma
12/24
12/24
CHARGE, NCT04315233: Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

Recruiting
1
34
US
Ribociclib, Belinostat
University of Utah, Novartis, Acrotech Biopharma
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
08/24
08/26

Download Options